

CURRICULUM VITAE

STEVEN M. RUBEN

Address: 19420 Pyrite Lane
Brookeville, MD 20833
(301) 774-7340
sruben@erols.com

Date and Place of Birth: April 20, 1956, Cleveland, Ohio

Social Security No.: 274-42-1919

Marital Status: Married, 2 children

Business Address: Celera Genomics
45 W. Gude Drive
Rockville, MD 20850
(301) 453-3929
steve.ruben@celera.com

Education:

1988 Ph.D., Cell/Molecular Biology Program, University of Cincinnati Cincinnati, OH
Ralph R. Meyer, Ph.D. Advisor, Thesis: Suppression of *Escherichia coli*
ssb-1 mutation by an allele of *groEL*

1985 M.S., Cell/Molecular Biology Program, University of Cincinnati,
Cincinnati, OH

1979 B.S., Biochemistry, Ohio State University, Columbus, OH

Professional Experience:

2003-Present Vice President Protein Therapeutics, Celera Genomics, Rockville, MD

1999-2003 Vice President Research, Human Genome Sciences, Rockville, MD

1996-1998 Director, Molecular Biology Department, Human Genome Sciences, Rockville, MD

1993-1996 Associate Director, Molecular Biology Department, Human Genome Sciences, Rockville, MD

1992-1993 Scientist, Molecular Biology Department, Human Genome Sciences, Rockville, MD

Steven M. Ruben
Appl. No. 10/662,429

Ruben EXHIBIT #13

1991-1992	Research Associate, Laboratory of Dr. Craig Rosen Department of Gene Regulation, Roche Institute of Molecular Biology, Nutley, NJ
1989-1992	Leukemia Society of America Fellow, Laboratory of Dr. Craig Rosen Department of Gene Regulation, Roche Institute of Molecular Biology, Nutley, NJ and Department of Microbiology, University of Medicine and Dentistry of New Jersey, Newark, NJ
1987-1989	Postdoctoral Fellow, Laboratory of Dr. Craig Rosen, Department of Molecular Oncology, Roche Institute of Molecular Biology, Nutley, NJ
1980-1986	Teaching Assistant, General Biology Laboratory, Department of Biological Sciences, University of Cincinnati, Cincinnati, OH

Research Experience:

Vice President Protein Therapeutics, Celera Genomics

- Direct oversight of Protein Therapeutic Staff, with 11 Ph.D.'s and 23 support staff with a research budget of 12.5 M
- Oversight of high throughput Mass Spectrometry Lab, Cell Biology Lab, and Tissue Acquisition efforts
- Co-ordination of discovery efforts for identification and validation of novel therapeutic opportunities for antibody, small molecule and diagnostic drugs using proteomic discovery platform and bioinformatics tools
- Leverage these opportunities with downstream antibody development provided by fully integrated biopharmaceutical companies. Instrumental in Genentech, Seattle Genetics and Abbott Laboratories-Celera alliance for co-development of mAb antibodies against differentially expressed tumor antigens, July-Sept. 2004. Member of JMC for Alliance partnerships
- Establish collaborative agreements with Medical institutions for the accrual of fresh tissue samples for proteomic platform

Vice President Research, Human Genome Sciences

- Direct oversight of the Preclinical Discovery Group with 13 Ph.D.'s and 53 support staff with a research budget of 13.7M
- Co-ordination across the Preclinical, Clinical, Regulatory and Protein Development Departments to identify therapeutic candidates and targets, validate the activities in vitro and in vivo and meet aggressive time lines for IND submissions. To date 3 gene, 2 antibody, and 1 gene therapy candidate have progressed through Preclinical development based on these efforts.
- Integration of Albumin fusion technology obtained from Principia Pharmaceuticals into discovery and development efforts. Nine candidates have progressed through advanced preclinical evaluation. One has entered Phase I studies.

- Establishment of pre-clinical yeast fermentation facility providing gram quantities of preclinical protein for in vitro and in vivo testing
- Oversight of the high throughput screening programs based on the Secretory Identification Program. To date, programs have been implemented for immune modulation, metabolic diseases and allergy/asthma. Collaborations have been established for a cardiovascular program and bone remodeling program
- Co-ordinate the transcriptional profiling program. This program includes arraying, quantitative PCR and database directed approaches. The arraying program has provided the basis of our Pharmacogenomics program, which supports both discovery efforts and clinical programs.
- Oversight and co-ordination of sequencing operations
- Established collaborations with multiple institutions to obtain both normal and tumor samples in an effort to identify cancer specific antigens.
- Established the HGS Antibody program through collaborations with Cambridge Antibody Technology and Abgenix.. Served on JRC for both collaborations. Oversight of initial development of the Anti-Blys (Lymphostat) program. Antibody Development Department was spun out from my group.
- Worked with Business Development to prepare out-licensing packages for novel candidates and in the assessment of new technology and opportunities to accelerate gene discovery and novel gene characterization
- Co-ordinate efforts with Patent and IT groups to establish and protect HGS intellectual property estate.
- Member of the Joint Research Council for Schering Plough collaboration
- Member of the Joint Research Council for Transgene collaboration
- HGS Chair of Joint Research Committee with Cambridge Antibody Technology and Abgenix

Director

- Responsibility for eleven Ph.D. scientists and support staff with a budget of 4.6M.
- Efforts included a secretory signal identification project. Aspects of this project included development of algorithms for selection of putative secreted proteins with the Bioinformatics Department, development of methodology for high throughput cloning, establishment of expression patterns using arrays, establishment of methods for stable and transient expression of secreted candidates and development of assay systems to identify biological activities of these molecules.
- A target identification project to identify small molecule targets was developed in the group in collaboration with the Bioinformatics group.
- Development of a transgenic and gene targeting facility within the department to complement the discovery program.
- Additional efforts within the department involved molecular biology support for IND candidates, discovery and characterization of potential therapeutic proteins, development of additional methods to "mine" the HGS database

Associate Director

- Responsible for seven Ph.D. scientists and support staff. The department focused on therapeutic protein identification and biological characterization of candidate genes.
- Co-ordinated the HGS cDNA library construction and sequencing schedules and pursued collaborations for novel tissue sources.
- Worked closely with the Bioinformatics Department to design and implement new strategies for organization of the database and candidate gene identification, including the strategies for secretory signal identification.
- Member of Joint Research Committee for Smith-Kline Beecham collaboration

Scientist:

- Research facilities setup, including equipment ordering, hiring, and framework for Bioinformatic interfaces for the EST database
- Focused on identification and characterization of novel therapeutic candidates from the HGS EST database. Candidates include a novel FAS ligand (Trail), a heart and lung specific DNase, and Stat6.
- Development of high-throughput sequencing template production using a PCR approach that was incorporated into the HGS template standard operating procedure.
- Member of the Research Steering Committee, for TIGR collaboration

Postdoctoral research:

As a research associate my work focused on the role that the *rel* family of proteins plays in the pathogenesis of both HIV-1 and HTLV-I. This family of proteins plays a critical role in activation of latent HIV virus. In addition, activation of these proteins by the HTLV-I Tax protein plays an important role in the pathways which lead to Adult T-cell Leukemia following HTLV-I infection. Using degenerate oligonucleotides

corresponding to highly conserved regions of the *rel* proteins as primers in PCR reactions using various cDNA's as template, three new *rel*-related proteins were identified, including the p65 subunit of NF-kB. Another one of these genes, I-Rel, is an inhibitor of NF-kB function. These genes were expressed for both mammalian expression and purification from *E. coli* and the transforming potential of these genes was measured using various assays. In addition, I directed a summer student and am directing the research of a post-doctoral fellow aimed at structure-function analysis of these proteins.

Prior postdoctoral research involved examination of the mechanisms of action of the viral regulatory proteins of HTLV-I and HIV-1 at both the nucleic acid and protein levels. This work emphasized the use of recombinant techniques of molecular biology as well as immunological analysis of protein expression in both eukaryotic and prokaryotic systems. Tissue culture work including transient and stable expression of viral genes was an integral part of this work. This work involved the construction and screening of cDNA libraries and isolation of monoclonal antibodies to study differential expression of cellular factors resulting from expression of viral proteins. The mechanism of action of the HIV-1 Tat protein was also studied at both the level of interaction with the RNA target sequence, Tar and direct protein-protein associations with a family of host proteins thought to be involved in regulation of transcription.

Graduate research:

My thesis research emphasized the use of molecular biological tools in studying protein-protein interactions of an *E. coli* DNA binding protein (SSB). This work resulted in identification of the initial *in vivo* interactions involving SSB and the heat shock protein Gro EL. In addition to the standard recombinant DNA methodology, this work involved the construction and screening of genomic libraries, protein purification, bacterial genetics, immunological techniques including Western blotting and RIA, and both *in vivo* and *in vitro* DNA synthesis studies.

Honors & Awards:

1989-1992	Leukemia Society of America Fellowship
1985-1987	University Research Council Fellowship, University of Cincinnati
1986	Outstanding Research Award, American Society for Microbiology, Ohio Branch
1982,1983	Harry L. Weiman Foundation Fellowship, Department of Biological Sciences, University of Cincinnati
1980-1987	Graduate Teaching Assistantship, Department of Biological Sciences, University of Cincinnati
1978	Distinguished Achievement in Biological Sciences, Ohio State University

Ad Hoc Reviewer:

Science
Virology
Molecular and Cell Biology
Journal of AIDS Research
Oncogene
Blood

Societies:

American Society for the Advancement of Science
American Society for Microbiology
American Diabetes Association

26. Papadopoulos, N, Nicolaides, NC, Wei, YF, **Ruben, SM**, Carter, KC, Rosen, CA, Haseltine, WH, Fleischmann, RD, Fraser, CM, Adams, MD, Venter, JC, Hamilton, SR, Petersen, GM, Watson, P, Lynch, HT, Peltomaki, P, Mecklin, JP, Chapelle, AD, Kinzler, KW & Vogelstein, B. (1994) Mutation of a mutL homolog in hereditary colon cancer. *Science* 263:1625-1629.
27. Nicolaides, NC, Papadopoulos, N, Liu, B, Wei, YF, Carter, KC, **Ruben, SM**, Rosen, CA, Haseltine, WH, Fleischmann, RD, Fraser, CM, Adams, MD, Venter, JC, Dunlop, MG, Hamilton, SR, Petersen, GM, Chapelle, AD, Vogelstein, B and Kinzler, KW. (1994) Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. *Nature* 371:75-80.
28. Quelle, FW, Shimoda, K, Thierfelder, W, Fischer, C, Kim, A, **Ruben, SM**, Cleveland, JL, Pierce, JH, Keegan, AD, Nelms, K, et al. (1995) Cloning of murine Stat6 and human Stat5, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. *Mol Cell Biol* 15(6):3336-43.
29. Coleman, TA, Huddleston, KA, **Ruben, SM**, Rosen, CA, and Gentz, R. (1997) Expression and Reconstitution of NF- \square B from Insect Cells Using a Baculovirus Vector. *Protein Expr Purif* 9:40-48.
30. Zeng, Z, Parmelee, D, Hyaw, H, Coleman, TA, Su, K, Zhang, J, Gentz, R, **Ruben, SM**, Rosen, C and Li, Y. (1997) Cloning and characterization of a novel human DNase. *Biochemical and Biophysical Research Comm* 231: 499-504.
31. Hu, J-S., Hastings, G.A., Cherry, S., Gentz, R., **Ruben, SM**, and Coleman, T.A. (1997) A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial and smooth muscle cells. *FASEB* 11:498-504.
32. Bui, TD., Rankin, J, Smith, K, Huguet, EL, **Ruben, SM**, Srachen, T, Harris, AL, and Lindsay, S. (1997) A novel human Wnt gene, WNT10B maps to 12q13 and is expressed in human breast carcinomas. *Oncogene* 14(10):1249-1253.
33. Mauri, DN, Ebner, R, Montgomery, RI, Kochel, KD, Cheung, TC, Yu, G-L, **Ruben, SM**, Murphy, M, Eisenberg, RJ, Cohen, GH, Spear, PG, Ware, CF. (1997) LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. *Immunity* 8(1):21-30.
34. Greene, JM, Li, Y-L, Yourey, PA, Gruber, J, Carter, KC, Shell, BK, Dillon, PA, Florence, C, Duan, DR, Blunt, A, Ornitz, DM, **Ruben, SM**, and Alderson, RF. (1998) Identification and characterization of a novel member of the fibroblast growth factor family. *Eur. J. Neurosci.* 10:1911-1925.
35. Haridas, V, Su, J, Yu, G, Ni, J, Chen, S, Ni, Y, **Ruben, S**, Shrivastava, A, Gentz, R, and Aggarwal, B. (1999) VEGI, a New Member of the TNF Family Activates Nuclear Factor- κ B and c-Jun N-Terminal Kinase and Modulates Cell Growth. *Oncogene* Nov 11;18(47):6496-504.

36. Phillips, T, Ni, J, Pan, G, **Ruben, SM**, Wei, Y-F, and Hunt, JS. (1999) TRAIL (Apo-2L) and TRAIL Receptors in Human Placentas: Implications for Immune Privilege. *J. Immunol.* 162:6053-6059.
37. Zhai, Y, Ni, J, Jiang, GW, Lu, J, Xing, L, Lincoln, C, Janat, F, Kozak, D, Rojas, L, Aggarwal, B, **Ruben, S**, Li, L, Gentz, R, Yu, G.-L. (1999) VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinoma *in vivo*. *FASEB J.* 13:181-189.
38. Zhai, Y, Guo, R, Hus, T-L, Yu, G-L, Ni, J, Kwon, BS, Jian, G.-W, Lu, J, Tan, J, Ugustus, M, Carter, K, Rojas, L, Zhu, F, Lincoln, C, Endress, G, Xing, L, Wang, S, Oh, K-O, Gentz, R, **Ruben, S**, Lippman, ME, Hsieh, S-L, and Yang, D. (1998) LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses *in vivo* tumor formation via gene transfer. *J Clin Invest.* 102:1142-1151.
39. Patel, VP, DeSilva, RT, White, B, Carrell, JA, Parmelee, D, Hilbert, DM, **Ruben, SM**, Gentz, R, and Garotta, G. (1999) The human β -chemokine MPIF-1 protects myeloid progenitors from cytotoxic effects of chemotherapeutic drugs *in vitro* and *in vivo*. *In Press*
40. **Ruben, S.** (1999) Use of genomic tools in the identification of bone-related therapeutics. *Bone* 25:81-83.
41. Xia, Y-P, Zhao, Y, Marcus, J, Jimenez, PA, **Ruben, SM**, Moore, PA, Khan, F, and Mustoe, AA. (1999) Effects of keratinocyte growth factor-2 (KGF-2) on wound healing in an ischemia-impaired rabbit ear model and scar formation. *J Pathol.* Aug;188(4):431-8.
42. Moore, PA, Belvedere, O, Orr, A, Pieri, K, LaFleur, DW, Feng, P, Soppet, D, Charters, M, Gentz, R, Parmelee, D, Li, Y, Galperina, O, Giri, J, Roschke, V, Nardelli, B, Carrell, J, Sosnovtseva, S, Greenfield, W, **Ruben, SM**, Olsen, HS, Fikes, J, Hilbert, DM. (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. *Science* 285:260-263.
43. Shi, Y, Wang, W, Yourey, PA, Gohari, S, Zukauskas, D, Zhang, J, **Ruben, S**, Alderson, RF. (1999) Computational EST database analysis identifies a novel member of the hematopoietic cytokine family. *Biochem Biophys Res Commun* 262:132-138.
44. Rosen, C, Fannon, M, Garotta, G, **Ruben, S.** (1999) A Genomics Approach to Cytokine Discovery. In *The Cytokine Network: Frontiers in Molecular Biology*. Balkwill, F (ed), Oxford University Press, Oxford, United Kingdom,.
45. Cossman J, Vockley J, Carter K, **Ruben S**, Louis Staudt L, Barash S, Birse C, Rosen C, Dolginow D, Lennon G (1999) Genome-wide gene expression of the rare, malignant Reed-Sternberg cell of Hodgkin lymphoma *Nat. Genet.*: 23, 40 (Poster Abstracts)
46. Giovarelli M, Musiani P, Garotta G, Ebner R, Di Carlo E, Kim Y, Cappello P, Rigamonti L, Bernabei P, Novelli F, Modesti A, Coletti A, Ferrie AK, Lollini PL, **Ruben S**, Salcedo T, Forni G. (1999) A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. *J. Immunol.* 163(9):4886-93.

13. **Ruben, SM** and Rosen, CA. (1990). Constitutive expression of the HTLV-I Tax protein suppresses signals required for activation of the transcription factor, NFkB. *New Biologist* 2:894-902.
14. Rosen, C A and **Ruben, SM.** (1991), Regulation of Human Retroviruses. *Drug News and Perspectives*, 4:340-351.
15. **Ruben, SM**, Dillon,PJ, Schreck, R, Henkel, T, Chen, C-H, Maher, M, Baeuerle PA, and Rosen, CA. (1991) Isolation of a *rel* related human cDNA that potentially encodes the 65kD subunit of NFkB. *Science* 251:1490-1493.
16. Rosen, CA, and **Ruben, SM**, Function of human retrovirus regulatory proteins. (1991) in *Annual Review of Medicinal Chemistry*, ed. C. Plattner, 171-180.
17. **Ruben, SM**, Narayanan, R, Klement, JF, and Rosen, CA. (1992) An alternatively spliced form of NF-kB p65 defines an essential functional domain, *Mol Cell Biol* 12:244-255.
18. **Ruben, SM**, Klement, JF, Maher, M, Coleman, TA, Chen, C.-H.,and Rosen, CA. (1992) I-Rel: A novel rel-related protein that inhibits NF-kB transcriptional activity. *Genes Develop* 6:745-760.
19. Narayanan, R, Klement, JF, **Ruben, SM**, Higgins, K, and Rosen, CA. (1992) Identification of a naturally occurring transforming varient of the p65 subunit of NF-kB. *Science* 256:367-370.
20. Kunsch, C, **Ruben, SM**, and Rosen, CA. (1992) Selection of optimal kB/Rel DNA binding motifs: Interaction of both subunits of NF-kB with DNA is required for transcriptional activation. *Mol Cell Biol* 12:4412-4421.
21. Rosen, CA, Dillon, PJ, Olsen, HS, and **Ruben, SM.** (1992) Complexities of Human Retrovirus Gene Expression, p.235-254 in *Genome Research in Molecular Medicine and Virology.*, Academic Press, Inc., Orlando, FL, ed. K.W. Adolf.
22. **Ruben, SM**, Beg, AA, Scheinman, RI, Haskill, S, Rosen, CA, and Baldwin, Jr. AS. (1992) IkB/MAD-3 interacts with the nuclear localization sequences of the subunits of NF-kB: a mechanism for cytoplasmic retention. *Genes and Develop* 6:1899-1913.
23. Moore, P, **Ruben, SM**, and Rosen, CA. (1993) Conservation of transcriptional activation functions of the NF-kB p50 and p65 subunits in mammalian cells and *Saccharomyces cerevisiae*. *Mol Cell Biol* 13: 1666-1674.
24. Ohana, B, Moore, P, **Ruben, SM**, Southgate, CD, Green, M, and Rosen, CA. (1993) The type 1 HIV Tat binding protein is a transcriptional activator belonging to an additional family of evolutionarily conserved genes. *Proc. Natl. Acad. Sci.* 90:138-142
25. Coleman, T.A., Kunsch, C., Maher, M., **Ruben, SM**, and Rosen, C.A. (1993) Acquisition of NFkB1-selective DNA-binding by substitution of four amino acid residues from NFkB1 into RelA. *Mol. Cell. Biol* 13:3850-3859.

Publications:

1. Meyer, RR, Voegele, DW, **Ruben, SM**, Rein, DC, and Trela, JM. (1982) Influence of single-strand DNA-binding protein on *RecA* induction in *Escherichia coli*. *Mutat. Res.* June;94(2):299-313.
2. **Ruben, SM**, Van Den Brink, SW, Rein, DC, and Meyer, RR (1985). Protein interactions of single-stranded DNA-binding protein determined by second-site revertent analysis. *Ohio J. of Science* 85: 62.
3. Meyer, RM, **Ruben, SM**, Van Den Brink-Webb, SE, Laine, PS, Perrino, FW, and Rein, DC. (1988) Protein-protein interactions of *Escherichia coli* single-stranded DNA-binding protein. In *DNA Replication and Mutagenesis*, R.E. Moses and W.C. Summers, eds., American Society for Microbiology, Washington, DC, pp. 154-162.
4. **Ruben, SM**, Van Den Brink-Webb, SE, Rein, DC, and Meyer, RR. (1988) Suppression of the *escherichia coli* *ssb-1* mutation by an allele of *groEL*. *Proc. Natl. Acad. Sci. USA* June;85(11):3767-71.
5. **Ruben, S**, Poteat, H, Tan, T.-H, Kawakami, K, Roeder, R, Haseltine, W, and Rosen, CA. (1988) Cellular transcription factors and regulation of interleukin-2 receptor gene expression by human T-cell leukemia virus *tax* gene product. *Science* Jul 241(1):89-91.
6. **Ruben, S**, Perkins, A, Purcell, R, Joung, K, Sia, R, Burghoff, R, Haseltine, WA, and Rosen, CA. (1989) Structural and functional characterization of the human immunodeficiency virus *tat* protein. *J. Virol.* Jan 63(1):1-8.
7. Perkins, A, Cochrane, AW, **Ruben, SM** and Rosen, CA. (1989). Structural and functional characterization of the human immunodeficiency virus *rev* protein. *J. Acquir Imm Def Syndr* 2:256-263.
8. Cochrane, A., Kramer, R., **Ruben, S**, Levine, J. and Rosen, C.A. (1989). The human immunodeficiency virus *rev* protein is a nuclear phosphoprotein. *Virology* 171:264-266.
9. Cochrane, A.W., Golob, E., Volsky, D., **Ruben, S**, Rosen, C.A. (1989) Functional significance of phosphorylation to human immunodeficiency virus *rev* protein. *J. Virol.* 63:4438-4440.
10. Cochrane, A., **Ruben, S.**, Nelbock, P. and Rosen, C. A. (1989) Functional and structural domains of the human immunodeficiency virus transacting regulatory proteins *tat* and *rev* in *Human Retroviruses*. Vol. 119, Alan Liss, Inc.
11. **Ruben, SM**, Perkins, A, and Rosen, CA. (1989) Activation of NFkB by the HTLV-I trans-activator protein requires an additional factor present in lymphoid cells. *New Biologist* 1:275-284.
12. Kramer, R.A., Tomchak, L., **Ruben S**, and Rosen, CA. (1990) Yeast cells expressing the *tax* gene of Human T-cell Leukemia Virus Type I exhibit a Flocculation phenotype identical to *FLO1* mutants. *Aids Research and Human Retroviruses* 6:1305-1309.

47. Yu R, Mandlekar S, **Ruben S**, Ni J, Kong AN. (2000) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. *Cancer Res.* 60(9):2384-9.

48. Hamil KG, Sivashanmugam P, Richardson RT, Grossman G, **Ruben SM**, Mohler JL, Petrusz P, O'Rand MG, French FS, Hall SH. (2000) HE2beta and HE2gamma, new members of an epididymis-specific family of androgen-regulated proteins in the human. *Endocrinology.*;141(3):1245-53.

49. Giovarelli M, Cappello P, Forni G, Salcedo T, Moore PA, LeFleur DW, Nardelli B, Carlo ED, Lollini PL, **Ruben S.**, Ullrich S, Garotta G, Musiani P. (2000) Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. *J Immunol.* 164(6):3200-6.

50. Richardson, R., Sivashanmugam, P., Hall, S.H., Hamil, K.G., **Ruben SM**, French, F.S., Moore, P. and O'Rand, M.G. (2000) Cloning and sequencing of human *Eppin*: A novel family of protease inhibitors expressed in the epididymis and testis. *Gene* 270:93-102.

51. Yu, R, Mandlekar, S, **Ruben, S**, Ni, J, Kong, AN. (2000) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. *Cancer Res.* 60(9):2384-9.

52. Shi Y, Ullrich SJ, Zhang J, Connolly K, Grzegorzewski KJ, Barber MC, Wang W, Wathen K, Hodge V, Fisher CL, Olsen H, **Ruben SM**, Knyazev I, Cho YH, Kao V, Wilkinson KA, Carrell JA, Ebner R. (2000) A novel cytokine receptor-ligand pair. Identification, molecular characterization, and *in vivo* immunomodulatory activity. *J Biol Chem.* ;275(25):19167-76.

53. Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, Dimke D, LaFleur D, Migone TS, Nardelli B, Wei P, **Ruben SM**, Ullrich SJ, Olsen HS, Kanakaraj P, Moore PA, Baker KP. (2000) Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. *J Biol Chem.*; 275(45):35478-85.

54. Wei, P, Zhao, YG, Zhuang, L, **Ruben, SM**, Sang ,QX. (2001) Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta. *Biophys Res Commun.* 280(3):744-55.

55. Richardson RT, Sivashanmugam P, Hall SH, Hamil KG, Moore PA, **Ruben SM**, French FS, O'Rand M (2001) Cloning and sequencing of human Eppin: a novel family of protease inhibitors expressed in the epididymis and testis. *Gene.*;270(1-2):93-102.

56. LaFleur, DW, Nardelli, B, Tsareva, T, Mather, D, Feng, P, Semenuk, M, Taylor, K, Buergin, M, Chinchilla, D, Roshke, V, Chen, G, **Ruben, SM**, Pitha, PM, Coleman, TA, Moore, PA. (2001) Interferon-kappa, a novel type i interferon expressed in human keratinocytes. *J Biol Chem.* ;276(43):39765-71.

57. Wei P, Zhao YG, Zhuang L, Hurst DR, **Ruben S**, Sang QX. (2002) Protein engineering and properties of human metalloproteinase and thrombospondin 1. *Biophys Res Commun.* 293(1):478-488
58. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu Gentz R, Feng P, Moore PA, **Ruben SM**, Wei P. (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. *Immunity*;16(3):479-92.
59. Barber TD, Barber MC, Tomescu O, Barr FG, **Ruben S**, Friedman TB. (2002) Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. *Genomics*;79(3):278-84.
60. Chen C, Grzegorzewski K, Barash S, Zhao Q, Schneider H, Wang Q, Singh M, Pukac L, Bell A, Duan R, Coleman T, Duttaroy A, Cheng S, Hirsch J, Zhang L, Lazard Y, Fischer C, Barber MC, Ma ZD, Zhang YQ, Reavey P, Zhong L, Teng B, Sanyal I, **Ruben, SM**, Blondel, O, Birse CE, (2003) An integrated Functional screening program reveals a role for BMP-9 in glucose homeostasis. *Nat. Biotechnol.* ;21(3):294-301
61. Fiscella M, Perry JW, Teng B, Bloom B, Zhang C, Leung K, Pukac L, Florence K, Concepcion A, Liu B, Meng Y, Chen C, Elgin EC, V, Kanakaraj P, Kaufmann TE, Porter J, Cibotti R, Mei Y, Zhou J, Chen G, Roschke V, Koumatsoulis G, Mansfield B, **Ruben S**, Sanyal I and Migone T-S. (2003) TIP, a novel T-cell factor identified using high-throughput screening increases survival in a graft-versus-host-disease model. *Nat. Biotechnol.* 21(3):302-7
62. Hamil KG, Liu Q, Sivashanmugam P, Anbalagan M, Yenugu S, Soundararajan R, Grossman G, Rao A, Birse CE, **Ruben SM**, Richardson RT, Zhang YL, O'Rand MG, Petrusz P, French FS, Hall SH. (2003) LCN6, a novel human epididymal lipocalin. *Reprod Biol Endocrinol*;1(1):112.
63. Edwards BM, Barash SC, Main SH, Choi GH, Minter R, Ullrich S, Williams E, Du Fou L, Wilton J, Albert VR, **Ruben SM**, Vaughan TJ. (2003) The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. *J Mol Biol.* :334(1):103-18.
64. Yenugu S, Hamil KG, Birse CE, **Ruben SM**, French FS, Hall SH. (2003) Antibacterial properties of the sperm-binding proteins and peptides of human epididymis 2 (HE2) family; salt sensitivity, structural dependence and their interaction with outer and cytoplasmic membranes of *Escherichia coli*. *Biochem J.*;372(Pt 2):473-83.

Presentations

1. "Identification of novel human genes through high throughput random sequencing" Large-scale DNA Sequencing International Symposium, Kokuritsu Kyoiku Kaikan, Tokyo, March 16-18, 1994.

2. "Use of high-throughput analysis of sequences for the discovery of novel therapeutics and diagnostics" Impact of Genomics on Inflammation Research, New York Academy of Sciences, New York, NY, October 18, 1995
3. "Use of high-throughput analysis of sequences for the discovery of novel therapeutics and diagnostics" Genome-Based Drug Discovery, International Business Communications, Marina Del Ray, CA, March 21-22, 1996.
4. "Utilizing High Throughput Sequencing for the Discovery of Novel Therapeutics and Diagnostic Targets" The Application of Genomics to Drug Discovery, Strategic Research Institute, Philadelphia, PA, May 30-31, 1996.
5. "Contributions of Genomics to Discovery of New Targets for Neuroscience Medicine" 6th World Congress of Biological Psychiatry, Nice, France, June 22-27, 1997.
6. "Use of Large cDNA Databases Toward the Discovery of New Therapeutic Proteins" Drug Discovery Technology '97, International Business Communications Group, San Diego CA, August 11-14, 1997.
7. "From Sequencing to Clinic: Use of cDNA Databases Toward the Discovery of Therapeutic Proteins" MIT Club, Washington DC, January 22, 1998.
8. "Discovery and Development of Novel Therapeutic Proteins: From EST's to Disease Models" Functional Genomics: From Identifying Proteins to Faster Drug Discovery, The National Managed Health Care Congress, Washington DC, March 10-11, 1998.
9. "Use of Genomic Tools in the Identification of Bone-related Therapeutics" ASBMR/IBMS Joint Meeting, San Francisco, CA, December 2, 1998.
10. "From Genomics to Drugs: A New Gene Based Drug Discovery Paradigm" The Third Annual Biopharmaceutical Industry Outlook and Opportunities Conference and Exhibition, Frost and Sullivan, Philadelphia, PA June 8-9, 1999.
11. "The Discovery and Development of Novel Clinical Candidates Using EST Database Approaches" Chairperson and Presenter, IBC's 4th Annual International Conference on Functional Genomics, Seattle, WA, October 4-6, 1999.
12. "Integrating Genomics into Antibody Discovery" Future Trends in Therapeutic Antibodies, SMI Conference, London, England, June 28-29, 2000.
13. "Utilizing Genomic Approaches to Accelerate Drug Discovery and Development" Drug Discovery Technology 2000, International Business Communications, Boston, MA, August 14-17, 2000.
14. "Utilizing Genomic Approaches for Accelerated Drug Discovery", Proteomics IBC Symposium, Lictchfield Park AZ, October 16-17, 2000

15. "Acceleration of the Drug Discovery Process through Genomics," The Impact of Genomics on Drug Discovery and Development, Keystone Symposia, Santa Fe, NM, February 2-7, 2001.
16. "Utilizing Genomic Approaches for Accelerated Drug Discovery," Genomic 2001 Tri-Conference, CHI, San Francisco, CA, March 7, 2001.
17. "Drug Discovery through Functional Genomics Approaches" University of Maryland, School of Medicine, Baltimore, MD, March 22, 2001.
18. "Genomics: Where are We Now and Where are We Going", Invited Panel Discussion, Burnill & Co, San Francisco, CA, May 8, 2001.
19. "Utilizing Genomic Approaches for Accelerated Drug Discovery" University of Maryland, College Park, MD, May 15, 2001.
20. "Regenerative Medicine as Alternative Medicine, Technologies at the Crossroads:Frontiers of the Future", ATP National Meeting, Baltimore MD, June 3-5, 2001
21. "Acceleration of the Drug Discovery Process through Genomics" Strategic Research Institute, Princeton NJ, July 16-18, 2001.
22. "Novel Approaches to Drug Discovery and Development" The Impact of Genomics and Proteomics on Medicine, American Association for the Advancement of Science, Washington, DC, September 25, 2001.
23. "Accelerating the Drug Discovery Effort through Genomics" Frontiers in Science Seminar series, Case Western Reserve University, Department of Chemistry, Cleveland, OH, January 16, 2003
24. "Post Genomic Approaches for the discovery of Novel Therapeutic Opportunities", Southwest Oncology Group "Annual Meeting, Huntington Beach, CA, March 28, 2004

Patents

Granted US Patents:

1. Macrophage inflammatory protein -3 and -4. U.S. Patent 5,504,003. April 1996.
2. Polynucleotide encoding macrophage inflammatory protein gamma. U.S. Patent 5,556,767. September 1996.
3. Paraoxonase. U.S. Patent 5,629,193. May 1997.
4. DNA encoding an interleukin-6 splice variant. U.S. Patent 5,641,657. June 1997.
5. Nucleic acid encoding a human G-protein receptor HPRAJ70 and method of producing the receptor. U.S. Patent 5,756,309. May 1998.
6. Nucleic acid encoding novel human G-protein coupled receptor. U.S. Patent 5,763,218. June 1998.
7. Human G-protein receptor HGBER32. U.S. Patent 5,776,729. July 1998.
8. Paraoxonase polypeptides and use thereof. U.S. Patent 5,792,639. August 1998.

9. Gene encoding human Dnase. U.S. Patent 5,830,744. November 1998.
10. Polynucleotide encoding a human chemotactic protein. U.S. Patent 5,866,373. February 1999.
11. Human G-protein receptor HCEGH45. U.S. Patent 5,869,632. February 1999.
12. Human chemotactic protein. U.S. Patent 5,880,263. March 1999.
13. Polynucleotides encoding extra cellular/epidermal growth factor HCABA58X polypeptides. June 1999.
14. Human G-protein coupled receptor. U.S. Patent 5,932,702. August 1999.
15. Human G-protein receptor HPRAJ70. U.S. Patent 5,948,890. September 1999.
16. Polynucleotides Encoding Extracellular/Epidermal Growth Factor HCABA58X Polypeptides. U.S. Patent No. 5,916,769. June 1999.
17. Polynucleotides encoding G-protein parathyroid hormone receptor HLTDG74 polypeptides. U.S. Patent 6,030,804. February 2000.
18. Novel Metalloproteinases. U.S. Patent 6,046,031. April 2000.
19. Polynucleotides encoding a cardiotrophin-like cytokine. U.S. Patent 6,046,035. April 2000.
20. Human Chemotactic protein. U.S. Patent 6,075,124. June 2000.
21. Isolated human PRT1 protein. U.S. Patent 6,093,795. July 2000.
22. Polynucleotides encoding a human chemotactic protein. U.S. Patent 6,100,389. August 2000.
23. Human blue-light photoreceptor hCRY2. U.S. patent 6,114,503. September 2000.
24. Polynucleotides encoding paraoxonase. U.S. patent 6,140,093. October 2000.
25. Anti-microbial peptide. U.S. patent 6,143,498 November 2000.
26. Cortistatin Polypeptides. U.S. patent 6,232,100. May 2001.
27. Gene encoding human Dnase. U.S. patent 6,251,648. June 2001
28. Nucleic acids encoding tumor necrosis factor receptor 5. U.S. patent 6,261,801. July 2001
29. Human oncogene induced secreted protein I. U.S. patent 6,284,486. September 2001
30. Nucleic acids encoding the G-protein coupled receptor HNFDS78. U.S. patent 6,287,801. September 2001
31. U.S. patent 6,294,169 Full-Text Interleukin-1 beta converting enzyme like apoptotic protease-6. September 2001
32. U.S. patent 6,303,338 Full-Text Pancreas-derived plasminogen activator inhibitor. October 2001
33. U.S. patent 6,312,937 Full-Text Metalloproteinases. November 2001
34. U.S. patent 6,316,225 Full-Text Human Prt1-like subunit protein (hPrt1) polynucleotides. November 2001
35. G-protein parathyroid hormone receptor HLTDG74. U.S. patent 6,338,951. January 2002
36. Secreted protein HLHFP03. U.S. patent 6,342,581. January 2002
37. Nucleic acid molecules encoding Follistatin-3. U.S. patent 6,372,454. April 2002
38. Polynucleotides encoding chemokine .alpha.-6. U.S. patent 6,372,456. April 2002
39. Tissue plasminogen activator-like protease. U.S. patent 6,372,473. April 2002
40. Human G-protein receptor HPRAJ70. U.S. patent 6,372,891. April 2002
41. Polynucleotides encoding chemokine .beta.-6 antagonists. U.S. patent 6,379,926. April 2002
42. Human DNA mismatch repair proteins. U.S. patent 6,380,369. April 2002
43. Polynucleotides encoding chemokine.alpha.-5. U.S. patent 6,395,514. May 2002

44. Cornichon-like protein. U.S. patent 6,410,709. June 2002
45. Human DNA mismatch repair proteins. U.S. patent 6,416,984. July 2002
46. Human chemotactic protein. U.S. patent 6,419,917. July 2002
47. Antimicrobial peptide. U.S. patent 6,420,116. July 2002
48. 186 human secreted proteins. U.S. patent 6,420,526. July 2002
49. Secreted protein HPEAD48. U.S. patent 6,433,139. August 2002
50. Keratinocyte derived interferon. U.S. patent 6,433,145. August 2002
51. Vanilloid receptor-2. U.S. patent 6,444,440. September 2002
52. Peptidoglycan recognition proteins. U.S. patent 6,444,790. September 2002
53. Testis expressed polypeptide. U.S. patent 6,448,230. September 2002
54. Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides. U.S. patent 6,451,562. September 2002
55. Galectin 9 and 10S V polynucleotides U.S. Patent 6,468,768
56. Keratinocyte derived interferon U.S. Patent 6,472,512
57. 94 Human Secreted Proteins U.S Patent 6,475,753
58. Secreted protein HNFGF20 U.S. Patent 6,476,195
59. Apoptosis inducing molecule II U.S. Patent 6,479,254
60. Human DNA mismatch repair polynucleotides. U.S. Patent 6,482,606
61. Interleukin 17-like receptor protein. U.S. Patent 6,482,923
62. Interleukin-20. U.S. Patent 6,486,301
63. Macrophage inflammatory protein-4 (MIP-4) polypeptides. U.S. Patent 6,488,925
64. Human ependymin. U.S. Patent 6,489,138 December 2002
65. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) . U.S. Patent 6,495,129
66. Apoptosis Inducing Molecule II and methods of use. U.S. Patent 6,495,520
67. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2. U.S. Patent 6,503,184 January 2003
68. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2. U.S. Patent 6,509,173
69. Polynucleotides encoding human G-protein chemokine receptor (CCR5) HDGNR10. U.S. Patent 6,511,826
70. Polynucleotides encoding cortistatin polypeptides. U.S. Patent 6,524,826
71. Precerebellin-like protein. U.S. Patent 6,525,174
72. Secreted protein HEMCM42. U.S. Patent 6,531,447
73. Bone marrow-specific protein. U.S. Patent 6,534,485 March 2003
74. Secreted protein HT5GJ57. U.S. Patent 6,534,631
75. Follistatin-3. U.S. Patent 6,537,966
76. Synferon. U.S. Patent 6,548,063
77. 49 human secreted proteins. U.S. Patent 6,566,32549 human secreted proteins. U.S. Patent 6,566,32
78. Human serine protease and serpin polypeptides. U.S. Patent 6,566,498
79. Human DNase. U.S. Patent 6,569,660
80. Protein HLQDR48. U.S. Patent 6,569,992
81. Human blue-light photoreceptor hCRY2. U.S. Patent 6,569,994
82. Chemokine .alpha.-4. U.S. Patent 6,576,445
83. Polynucleotides encoding T1 receptor like ligand II. U.S. Patent 6,586,210
84. Secreted protein HODAZ50. U.S. Patent 6,590,075
85. Human DNA mismatch repair proteins. U.S. Patent 6,610,477 August, 2003
86. T1 receptor-like ligand II and uses thereof. U.S. Patent 6,605,271

87. Protein HOFNF53. U.S. Patent 6,605,592
88. Human DNA mismatch repair proteins. U.S. Patent 6,610,477
89. Human DNA mismatch repair protein. U.S. Patent 6,620,619
90. Dendritic enriched secreted lymphocyte activation molecule. U.S. Patent 6,620,912
91. Nucleic acids encoding human tumor necrosis factor TR20. U.S. Patent 6,623,941
92. Macrophage inflammatory protein-4 (MIP-4) . U.S. Patent polynucleotides. U.S. Patent 6,623,942
93. Antibodies to secreted protein HCEJQ69. U.S. Patent 6,627,741
94. 36 human secreted proteins. U.S. Patent 6,632,920
95. HMCIS41. U.S. Polynucleotides encoding a novel interleukin receptor. termed interleukin-17 receptor-like protein. U.S. Patent 6,635,443
96. Apoptosis inducing molecule II and methods of use. U.S. Patent 6,635,743
97. Pancreas-derived plasminogen activator inhibitor . U.S. Patent 6,649,738
98. T1 receptor-like ligand II polypeptides. U.S. Patent 6,667,032 December 2003
99. Human ependymin. U.S. Patent 6,683,161 January 2004
100. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 6,689,607 February 2004
101. Keratinocyte growth factor-2. U.S. Patent 6,693,077 February, 2004
102. Heregulin-like factor. U.S. Patent 6,727,077 April 2004
103. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) . U.S. Patent 6,743,594 June 2004
104. Lysyl-oxidase HOHEC84 polynucleotides. U.S. Patent 6,743,613 June 2004
105. Nucleic acids encoding human serpin polypeptide Patent 6,753,164 June 2004
106. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 6,503,184 January 2004
107. Protein HOFNF53 U.S. Patent 6,605,592 August 2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.